Regeneron Pharmaceuticals, Inc.REGN
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $14.92B, growing 5.9% year-over-year. TTM net income stood at $4.42B (1.7% contraction). Quarterly EBITDA was $766.10M and operating income was $642.90M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze REGN growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters